Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E TP53 Q192K |
Therapy | Panitumumab + Vemurafenib |
Indication/Tumor Type | colon cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E TP53 Q192K | colon cancer | predicted - sensitive | Panitumumab + Vemurafenib | Case Reports/Case Series | Actionable | In a clinical case study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312). | 28514312 |
PubMed Id | Reference Title | Details |
---|---|---|
(28514312) | Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. | Full reference... |